Delivery Order SPE2DB22D9353-SPE2DB23FX1WP

Award Date 3/21/23
Potential Completion Date 4/11/23
Potential Value $82K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $82,041.50 and covers the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a larger single-award Indefinite Delivery Contract...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $40,142.85, is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. The contract has a completion date of June 25, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $90,117.40, is for the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $24,568.74 contract is for the delivery of 4,567,603,209 units of Keytruda 100 mg/4 ml vial (4 ml) to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the issuance...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $96,342.84, is for the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $49,137.36, is for the delivery of Keytruda 100 mg/4 ml vial (4 ml) to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,142.85 firm fixed-price contract is for the supply of Keytruda 100 mg/4 ml vial. The contract has an ultimate completion date of July 3, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $77,505.20, is for the delivery of 4560693899 KEYTRUDA 100 MG/4 ML VIAL 4ML to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $80,218.40, is for the delivery of Keytruda 100 mg/4 ml vials. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued up to $499,999,999, which allows the agency to issue firm fixed-price delivery orders for a comprehensive...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $80,218.40 contract is for the delivery of Keytruda 100 mg/4 ml vials. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a...
  • SPE2DB22D9353
    Indefinite Delivery Contract
  • SPE2DB22D9353-SPE2DB23FX1WP
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $81,507.72 and covers the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products. This contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

Generated 4/2/25, 5:33 PM